Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Blog

Controlling Impurities in Cell Culture Media

Evolving Challenges in Closed-System Biomanufacturing

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

Posters

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Product Brochures

ITSE AF – Brochure

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

Exbumin – Safety Data Sheet

ITSE AF – Safety Data Sheet

Optibumin – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Optiferrin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Emergence of Blood-Free Recombinant Human Albumin